尿素载体UT-A1作为低血症的新药标
Nannan Li1, Hang Zhang1, Shuyuan Wang1
1State Key Laboratory of Vascular Homeostasis and Remodeling, Department of Pharmacology, School of Basic Medical Sciences, Peking University, Beijing, China.
概括
针对尿素载体 (UTs) 的新利尿剂可以在没有电解质损失的情况下治疗低血症. UT-A1被确定为开发新型治疗不适当抗尿激素分泌综合征 (SIADH) 诱导的低血症的有希望的目标.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 低血症是一种常见的电解质失衡,需要新型利尿剂来保护电解质.
- 尿素运输体 (UTs) 对尿度至关重要,并且代表了利尿剂发展的潜在药物标.
研究的目的:
- 研究尿素运输体 (UTs) 作为治疗低血症的治疗点.
- 评估UT抑制剂在不适当抗尿激素分泌 (SIADH) 综合征的老鼠模型中的疗效.
- 使用淘汰赛小鼠模型,比较UT-A1和UT-B在SIADH诱导的低血症中的作用.
主要方法:
- 构建和分析老鼠和小鼠SIADH模型.
- 将UT抑制剂25a给低血性大鼠,并测量血清度和水平.
- 在抑制剂治疗后评估电解质平衡和脂质代谢.
- 用UT-A1和UT-B淘汰赛评估SIADH小鼠模型,以确定治疗点.
主要成果:
- UT抑制剂25a显著增加了血清度和水平在低血症大鼠通过利尿.
- 用25a治疗没有诱导其他电解质失衡或影响脂质代谢.
- 在SIADH模型中,UT-A1淘汰赛小鼠与UT-B淘汰赛小鼠相比,血清度和的减少较小.
结论:
- 对于治疗SIADH诱导的低血症,UT-A1是一个比UT-B更有前途的治疗标.
- UT-A1 抑制剂显示出作为治疗低血症的新型利尿剂的潜力.
- 这项研究提供了UT-A1作为低血症可行的药物点的概念证明.
更多相关视频
07:38Functional Characterization of Na+/H+ Exchangers of Intracellular Compartments Using Proton-killing Selection to Express Them at the Plasma Membrane
Published on: March 30, 2015
9.3K
09:12Selection of Transporter-Targeted Inhibitory Nanobodies by Solid-Supported-Membrane SSM-Based Electrophysiology
Published on: May 3, 2021
2.6K
相关概念视频
01:17Pore Transport and Ion-Pair Transport
417
Pore transport and ion-pair formation are critical mechanisms for the absorption and distribution of drugs in the body.
Pore transport, also known as convective transport, is a process where small molecules like urea, water, and sugars rapidly cross cell membranes as though there were channels or pores in the membrane. Although direct microscopic evidence is limited but the concept of pores or channels is widely accepted based on physiological evidence. Despite the lack of direct...
Pore transport, also known as convective transport, is a process where small molecules like urea, water, and sugars rapidly cross cell membranes as though there were channels or pores in the membrane. Although direct microscopic evidence is limited but the concept of pores or channels is widely accepted based on physiological evidence. Despite the lack of direct...
417
01:15Drug Elimination by Renal Route: Tubular Secretion
2.3K
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
2.3K
01:16Antihypertensive Drugs: Action of Diuretics
665
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
665
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.0K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.0K
01:28Renal Drug Excretion: Tubular Secretion
174
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
174
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
511
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
511